Athira Pharma, Inc. — Director's Dealing 2023

May 22, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2023-05-18

Reporting Person: Gengos Andrew (See Below)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-18	Stock Options (right to buy)	$2.84	A	400000	Acquired	2033-05-17	Common Stock (400000)	Direct

Footnotes

F1: One-third (1/3) of the shares subject to the option shall be scheduled to vest on May 18, 2024, the one (1) year anniversary of May 18, 2023, and the remaining shares subject to the option shall be scheduled to vest monthly over the next 36 months on the 18th of each month, subject to the Reporting Person continuing to be a Service Provider (as defined in Athira Pharma, Inc.'s 2020 Equity Incentive Plan) through the applicable vesting dates, as follows: one-third (1/3) of the shares subject to the option shall be scheduled to vest in equal monthly amounts over the next 12 months; one-sixth (1/6) of the shares subject to the option shall be scheduled to vest in equal monthly amounts over the subsequent 12 months; and the remaining one-sixth (1/6) of the shares subject to the option shall be scheduled to vest in equal monthly amounts over the final 12 months.